Takeda Sees Another Wave 1 Plan Come Crashing Down
The Phase III failure for pevonedistat in three rare blood cancer settings is the third setback for Takeda’s Wave 1 pipeline candidates this year. The NEDD8 inhibitor is still being studied in other settings.
You may also be interested in...
Setback for company's near-term launch goals and US patients with rare esophageal inflammatory condition as regulator asks for additional clinical data.
Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker